BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with AstraZeneca, a global, science-led biopharmaceutical company ...
Predictive Oncology aims to enhance drug discovery using its biobank and AI, following industry trends exemplified by Regeneron's 23andMe acquisition. Predictive Oncology Inc. is leveraging its ...
BostonGene has entered a new collaboration with AstraZeneca to apply its foundation AI model to oncology drug development, aiming to improve early trial decision-making around safety, efficacy, and ...
PITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor samples and drug response data ...
Overview: Predictive analytics is about action, not just forecasts. The best platforms explain trends and guide what to do ...
"Driven by EHR adoption, cost-efficiency goals, and IoT integration, the healthcare predictive analytics market is reshaping ...
Forbes contributors publish independent expert analyses and insights. David Henkin helps organizations and individuals innovate and grow. Predictive analytics has evolved from a niche discipline into ...
Update (Oct. 1, 00:30 UTC): This article has been updated to include comments from DNA Fund co-founder Chris Miglino. Predictive Oncology (POAI), a biotechnology company specializing in AI-driven ...
Predictive Oncology, Inc. (NASDAQ:POAI) shares are trading higher on Tuesday after the company announced it developed predictive models to target various cancer types. The Details: The models were ...
There is a vast array of predictive analytics tools, but not all are created equal. Software differs widely in terms of capability and usability — not all solutions can address all types of advanced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback